You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Les traitements par chimiothérapie et autres traitements systémiques pourraient être modifiés en raison de la COVID-19. Vous trouverez de plus amples renseignements à la page Traitements systémiques pendant la pandémie de la COVID-19.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Formulaire de médicaments
À propos du Formulaire de médicaments Courriel de l’équipe du Formulaire de médicaments

Médicaments

La bibliothèque de médicaments donne accès à des renseignements sur plus de 100 médicaments anticancéreux commercialisés au Canada.

Trouvez plus d’information sur la sécurité  dans le document patient supplémentaire Comment prendre vos médicaments oraux contre le cancer de manière sécuritaire.

Displaying Drugs List

172 articles
Other Name(s): Verzenio™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2020
Other Name(s): Zytiga® (Janssen)
Funding:
Exceptional Access Program
  • abiraterone - Metastatic castrate-resistant prostate cancer, with specific criteria
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2019
Other Name(s): Calquence®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Jan 2021
Other Name(s): Giotrif®
Funding:
Exceptional Access Program
  • AFAtinib - For first-line monotherapy treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Other Name(s): Proleukin® (interleukin-2)
Funding:
New Drug Funding Program
  • Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Other Name(s): Alecensaro™
Funding:
Exceptional Access Program
  • Treatment of non-small cell lung cancer according to clinical criteria
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Other Name(s): MabCampath®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2019
Other Name(s): AMSA P D® (Erfa)
Quick Link(s):
Drug Monograph
Sep 2011
Other Name(s): Agrylin® (Shire Pharma)
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2017
Other Name(s): Arimidex®
Funding:
ODB - General Benefit
  • anastrozole
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2020
Other Name(s): Erleada®
Funding:
Exceptional Access Program
  • apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2020
Other Name(s): Trisenox® (Lundbeck)
Funding:
New Drug Funding Program
  • Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - First Line Induction of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - Relapsed_Refractory Induction of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2016